Introduction: Several biological drugs and a new small molecule are available for the treatment of Crohn’s disease and ulcerative colitis. However, to date, no reliable predictors of response to treatment have yet been identified.

Areas covered: We focused on studies evaluating the therapeutic management of patients with chronic inflammatory bowel diseases in order to identify any predictive factors of response to drugs and to guide therapeutic decisions based on patient and disease characteristics.

Expert Opinion: The heterogeneity of literature data, the main retrospective nature of the scientific evidence, and the lack of comparative head-to-head trials are the most relevant limitations for identifying factors predicting drug response. In the near future, a personalized approach to patients with chronic inflammatory diseases will be based on patient’s profile to define not only the best drug to use, but also the appropriate follow-up, and the possibility of home care.

简介：几种生物药物和一种新的小分子可用于治疗克罗恩氏病和溃疡性结肠炎。然而，迄今为止，尚未确定对治疗反应的可靠预测因子。

涵盖的领域：我们专注于评估慢性炎症性肠病患者的治疗管理的研究，以便确定对药物反应的任何预测因素，并根据患者和疾病特征指导治疗决策。

专家意见：文献数据的异质性，科学证据的主要回顾性以及缺乏比较性的针锋相对的试验，是确定预测药物反应因素的最相关限制。在不久的将来，针对慢性炎性疾病的患者的个性化方法将基于患者的概况，不仅定义要使用的最佳药物，还应确定适当的随访措施以及家庭护理的可能性。